A New Resource for MPN patients
MPN Cancer Connection
Welcome to MPN Cancer Connection, where a brighter future for MPN treatments shines on the horizon with opportunity and resources for improved patient care.
Goals
1Number 1
MPN patients are in fact “cancer patients” and should have full access to programs and resources available in your area. Greater MPN Awareness via increased media exposure is needed.
2Number 2
Much needed funding for PV Reporter is also a focus. PV Reporter, one of the most comprehensive patient run MPN websites, offers a wealth of resources and information for MPN patients. Serving our community since 2013.
3Number 3
MPN Cancer Connection (MPN-CC) is a NON PROFIT (501-c-3) corporation, a public charity. Donations are tax deductible. Help us raise awareness!
What Are Myeloproliferative Neoplasms?
Myeloproliferative neoplasms (MPN) are a group of diseases that affect blood-cell formation. In all forms of MPN, a bone marrow problem leads to increased levels of blood cells circulating in the bloodstream.
1) “Myelo” refers to bone marrow, which is the body’s blood-cell factory.
2) “Proliferative” refers to the rapid growth and production of cells.
3) “Myeloproliferative” means increased growth and production of bone marrow and blood cells.
4) “Neoplasm” means an abnormal growth of cells, especially as a characteristic of cancer.
2) “Proliferative” refers to the rapid growth and production of cells.
3) “Myeloproliferative” means increased growth and production of bone marrow and blood cells.
4) “Neoplasm” means an abnormal growth of cells, especially as a characteristic of cancer.
Learn More
Learn more about MPN (Myeloproliferative Neoplasms)
David Wallace, the founder of MPN-CC and PV Reporter, on location at the 2015 American Society of Hematology (ASH) conference. Carol Preston talks with David about his work providing comprehensive MPN resources to patients and his positive outlook on combination therapies. Check out the video as it provides a nice overview of present and future projects.
Ruben Mesa, M.D., Deputy Director, Mayo Clinic Cancer Center, shares an update on the latest Myeloproliferative Neoplasm research and treatment for 2016.
Blog
September 21, 2016
“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in […]
September 20, 2016
Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in […]
August 30, 2016
THE STORY OF JAK2 Four teams race to find the mysterious cause of a group of blood cancers. Click the link below for the complete article…